Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans
Basa R, Davies V, Li X, Murali B, Shah J, Yang B, Li S, Khan M, Tian M, Tejada R, Hassan A, Washington A, Mukherjee B, Carethers J, McGuire K. Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans. PLOS ONE 2016, 11: e0156660. PMID: 27310868, PMCID: PMC4911070, DOI: 10.1371/journal.pone.0156660.Peer-Reviewed Original ResearchConceptsGranzyme B+ cellsColorectal cancerCytotoxic immunityB+ cellsAnti-tumor cytotoxic T lymphocytesColon cancerMicrosatellite-stable colon cancerCytotoxic T lymphocytesIL-17 expressionWilcoxon rank sum testProtection to patientsAfrican American colorectal cancerRank sum testTwo-sample Wilcoxon rank-sum testCD57+CD8+Invasive borderCytotoxic markersNo significant differenceT lymphocytesColon tumorsDescriptive summary statisticsImmune biomarkersTumor samplesImmune cytotoxicityMicrosatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Koi M, Garcia M, Choi C, Kim H, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen Y, Mukherjee B, Boland C, Carethers J. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016, 150: 944-955. PMID: 26752111, PMCID: PMC4808397, DOI: 10.1053/j.gastro.2015.12.032.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorChi-Square DistributionChromosome AberrationsChromosomes, Human, Pair 9Colorectal NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansJapanKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Republic of KoreaRisk FactorsTime FactorsTreatment OutcomeConceptsPrimary colorectal tumorsLoss of heterozygosityLiver metastasesColorectal cancerColorectal tumorsElevated microsatellite alterationsMicrosatellite alterationsStage IICurative treatment of patientsStage III colorectal cancerOverall survival of patientsSurvival of patientsIII colorectal cancerTumor to liverColorectal cancer recurrenceTreatment of patientsMatched liver metastasesCancer cell nucleiMatched metastasesDisease recurrenceOverall survivalPrognostic factorsAllelic lossNo significant differenceCurative treatment